More of a cautionary winter’s tale than a midsummer night’s dream, an Indiana farmer facing legal action from a certain biotech and chemical multinational behemoth recently reached the U.S. Supreme Court. The case is called Bowman v. Monsanto, and with all that hangs in the balance, a herbicide-resistant rose by any other name would, in […]
The Myriad Genetics gene patenting saga has officially shaped international jurisprudence, with the Federal Court of Australia upholding the patents for BRCA1 and BRCA2. In Cancer Voices Australia v. Myriad Genetics, NSD643/2010, Federal Court of Australia (Sydney), the first Australian case to deal with the issue of gene patents, the Court took a similarly liberal […]
Sparking Innovation With Students: Examining The Student Role From Invention To Commercialization Conference Chair Prof. Giuseppina D’Agostino Founder & Director, IP Osgoode Including Keynote Addresses from Sylvain Laporte Commissioner of Patents, Registrar of Trademarks and CEO, Canadian Intellectual Property Office Bill Mantel Assistant Deputy Minister – Research, Commercialization and Entrepreneurship Division Ontario Ministry of Research […]
IP Osgoode is pleased to announce that our very own Professor Giuseppina D’Agostino, Founder and Director of IP Osgoode, was featured on last Tuesday’s episode of The Agenda with Steve Paikin entitled “Is Innovation History?” The full video is available below.
It was 1999 when Research In Motion (RIM) first imprinted itself in the world of electronic communication. When the company reached its peak it was difficult to imagine that an innovative company such as RIM would sit idly by watching the market change. RIM’s lack of innovation compared to its competitors is what caused its […]
“It is a truth universally acknowledged that a single culture in possession of good traditional knowledge must be in want of intellectual property rights.”
As part of Osgoode’s Intellectual Property Law Intensive Program, I had the opportunity to spend ten weeks at Teva Canada working with in-house counsel. Teva Canada is one of Canada’s largest generic pharmaceutical companies that also has a brand division focusing on the development of innovative products in several therapeutic areas.
The Tokyo branch of Sony Corp. (creators of the Playstation 3 gaming system) filed a U.S. patent application in December 2012 for technology which would effectively put an end to second-hand game sales. The problem with second-hand “resell” games is that Sony doesn’t generate any income from the transactions. The patent application theorizes a method which would […]
Giuseppina D’Agostino is the Founder and Director of IP Osgoode, the Founder and Director of the IP Intensive Program, and an Associate Professor at Osgoode Hall Law School. 2012 was an action-packed year in the world of intellectual property law. There were flurries of reports, decisions, and new legislation that confronted many core principles of […]
The long battle in the American courts over Myriad Genetics’ patents of BRCA1 and BRCA2, the primary diagnostic genes for hereditary breast and ovarian cancer has been well-documented in the IPilogue (see coverage by Beatrice yesterday as well as previous posts here, here, and here). Now, Myriad is poised to defend their patents at the Supreme Court for a second time, with […]